可溶性CD_(40)配体和核转录因子PPARγ与冠状动脉病变的相关性研究  

Relationship of sCD_(40)L and expression of peroxisome proliferator-activated receptor γ(PPAR-γ)mRNA and coronary artery lesions in CHD patients

作　　者：杨丽霞[1] 杨玉霞[1] 齐峰[1] 郭传明[1] 王先梅[1] 石燕昆[1] 王燕[1] 

机构地区：[1]成都军区昆明总医院心内科,云南昆明650032

出　　处：《中国现代医学杂志》2006年第18期2792-2794,2800,共4页China Journal of Modern Medicine

摘　　要：目的探讨可溶性细胞表面分化抗原40配体(sCD40L)水平、核转录因子PPARγmRNA表达与冠状动脉病变的关系及其在冠心病发病中的意义。方法经冠状动脉造影确诊的冠心病患者,ELISA法检测血浆中sCD40L含量,RT-PCR法测定外周血中PPARγmRNA表达,并对冠状动脉病变程度进行分型,分析sCD40L水平、PPARγmRNA表达与冠状动脉病变程度的相关性。结果CHD组与对照组相比sCD40L明显增加(19.0±6.6vs13.4±3.8),PPARγmRNA明显降低(0.40±0.12vs0.62±0.13),尤以ACS组明显,且随冠状动脉病变累计支数越多、病变越严重,sCD40L水平增高,PPARγmRNA表达减少越显著。相关分析显示PPARγmRNA表达和sCD40L水平呈明显负相关(r=-0.43,P<0.001)。结论sCD40L对ACS不稳定斑块有促进作用,PPARγ具有抑制sCD40L的作用,提示通过激活PPARγmRNA表达和降低sCD40L水平可能对冠心病高危人群具有保护作用。[Objective] To investigate the mechanism of sCD40L, peroxisome proliferator-activated receptorγ （PPAR-γ）mRNA in coronary heart disease（CHD） by the relationship study among sCD40L, PPAR-γ and the severity of coronary lesions in coronary heart disease patients. [Methods] 98 patients with CHD who undergone coronary angiography were admitted, Enzyme Linked Immunosorent Assay was used to measure the level of sCD40L, the expression of PPAR-γ mRNA in lymphocytes located in peripheral blood was detected by using RT-PCR. The severity of coronary artery lesions was analyzed. The lesions of coronary artery was typified. [Results] sCD40L level was significantly higher in CHD patients than those in controls [（19.0±6.6） vs （13.4：±3.8）]. Significant decreasing is observed in CHD patients in PPAR-γ mRNA [（0.40±0.12） vs （0.62±0.13）]. The more the number of coronary artery lesions and severity of coronary artery lesions, the higher the level of sCD40L and the lower the expression of PPAR-γ mRNA. Negtive correlation were seen between PPAR-γmRNA and sCD40L level. [Conclusions] sCD40L accelerated the formation of unstable plaque, PPAR-γ inhibited the activation of sCD40L, PPAR-γ is a negtive regulator of coronary artery lesions. It will be a valuable method to protect patients from the incidents of coronary artery disease by acting the expression of PPAR-γ and decreasing the level of sCD40L.

关 键 词：可溶性CD40配体 核转录因子PPARr 冠状动脉病变 

分 类 号：R541.4[医药卫生—心血管疾病]